Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | FASN | P49327 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 6/20 | 0.35 |
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3315821 | 0.75 | ALDH1A1 (0.36) | ALDH1A1TSHRFASNFAAHPPARG | |
| SCHEMBL3315816 | 0.75 | ALDH1A1 (0.36) | ALDH1A1TSHRFASNFAAHPPARG | |
| SCHEMBL28640772 | 0.74 | TSHR (0.48) | ALDH1A1TSHRFASNFAAHCNR1 | |
| SCHEMBL21044846 | 0.72 | FASN (0.55) | ALDH1A1TSHRFASNFAAHPPARG | |
| SCHEMBL10318388 | 0.72 | ALDH1A1 (0.39) | ALDH1A1TSHRFASNFAAHCNR1 | |
| SCHEMBL28336472 | 0.71 | ALDH1A1 (0.36) | ALDH1A1TSHRFASNFAAHCNR1 | |
| SCHEMBL6473479 | 0.71 | — | — | |
| SCHEMBL574186 | 0.71 | — | — | |
| SCHEMBL6479729 | 0.71 | — | — | |
| SCHEMBL6473565 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675842-A1 | DIHYDROBENZOFURANYL ALKANAMINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Wyeth (US) | 2006-07-05 | — | — | EP | claimed |
| US-20050124692-A1 | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents | WYETH (US) | 2005-06-09 | — | — | US | claimed |
| WO-2005040146-A1 | DIHYDROBENZOFURANYL ALKANAMINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WYETH (US) | 2005-05-06 | — | — | WO | claimed |
| US-7728155-B2 | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents | WYETH LLC (US) | 2010-06-01 | — | — | US | disclosed |
| EP-1675842-A1 | DIHYDROBENZOFURANYL ALKANAMINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Wyeth (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20050124692-A1 | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents | WYETH (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2005040146-A1 | DIHYDROBENZOFURANYL ALKANAMINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WYETH (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124692-A1 | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents | HTR2C, HTR1A, HTR1B | ALDH1A1 185/4885TSHR 474/4885FASN 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.